Back to search
FDAFDA · Food and drugs·Recall number D-0004-2024

lidocaine 2%, 100 mg/5 mL, (20 mg/mL), 5 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6006-1

Published October 11, 2023 · Recall initiated: September 21, 2023

Summary

FDA records drug Class II recall D-0004-2024, published October 11, 2023 and initiated September 21, 2023. Recalling firm: Central Admixture Pharmacy Services Inc; Status: Terminated; Reported quantity: 1,992 5 mL syringes; Lot: Lot: 17-275788, Exp. 10/10/2023; 17-275872, Exp. 10/11/2023; 17-275922, Exp. 10/12/2023; 17-275972, 17-275973, Exp. 10/15/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of assurance of sterility:

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Central Admixture Pharmacy Services Inc
Distributor
Nationwide in the USA
Lot
Lot: 17-275788, Exp. 10/10/2023; 17-275872, Exp. 10/11/2023; 17-275922, Exp. 10/12/2023; 17-275972, 17-275973, Exp. 10/15/2023.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was lidocaine 2%, 100 mg/5 mL, (20 mg/mL), 5 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6006-1 recalled?

Yes. FDA published recall D-0004-2024 on October 11, 2023. Reported hazard: Lack of assurance of sterility:

What should I do if I have this product?

Voluntary: Firm initiated · Letter